Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Zenagamtide s.c. Once Weekly Compared to Placebo in Participants With Type 2 Diabetes and Chronic Kidney Disease Inadequately Controlled on Once Daily Basal Insulin Alone or in Combination With Metformin, SGLT2i, or Both

NCT07931547 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07931547 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Zenagamtide s.c. Once Weekly Compared to Placebo in Participants With Type 2 Diabetes and Chronic Kidney Disease Inadequately Controlled on Once Daily Basal Insulin Alone or in Combination With Metformin, SGLT2i, or Both
Lead sponsor
Novo Nordisk A/S
Phase
Phase 3
Overall status
Not yet recruiting
Start date
November 10, 2026
Completion date
September 25, 2028
Enrollment
450 (estimated)
Sites
125

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney disease, type 2 diabetes

Arms

As registered; 2 arms.

  • Placebo Placebo comparatorPlacebo

    Participants will receive placebo matched to zenagamtide subcutaneously.

  • Zenagamtide ExperimentalZenagamtide

    Participants will receive zenagamtide subcutaneously.

Primary endpoints

Registered primary outcome measures; 1 primary.

  • Change in glycated haemoglobin (HbA1c) From baseline (week 0) to week 52

    Measured in percentage (%)-points

Lead sponsor's other trials

Novo Nordisk A/S, most recent start first.

Similar trials

Same condition (Renal Insufficiency, Chronic) and phase, most recent start first.